• Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to Bluesky Link to BlueskyLink to Bluesky
  • Link to Instagram
  • ESO
  • ESOC 2026
  • ESOC 2027
  • STROKE INSIGHTS
  • eSTEP
  • MEMBERSHIP
  • SUPPORT US
THE VOICE OF STROKE IN EUROPE
European Stroke Organisation
  • About
    • What we do
    • Who we are
      • Leadership
      • ESO Committees
      • Honorary Members
      • Award Recipients & Awards Selection Committee
      • Young Stroke Physicians and Researchers Committee
      • DEI Advisory Council
      • Head Office
    • Membership
      • Benefits
      • Individual Membership
      • Organisational Membership
      • Membership Fees
    • Governance
      • Bylaws and Statues, Advocacy
      • Code of Conduct
    • History
    • Global Stroke Cooperation
  • Meetings
    • ESO Conference
    • ICH Academy Meeting (IAM)
    • Simulation Workshop 2026
    • Winter School
    • Summer School
    • Edinburgh Stroke Research Workshop
    • European Stroke Science Workshop
    • Focused Workshop
    • Educational Webinars
    • ESO Endorsed Meetings and Education
      • Applications for Endorsement
    • Events Calendar
  • Guidelines
    • ESO Guideline Directory
    • ESO Guideline Board
    • ESO Guideline Development Webinar
  • Projects
    • ANGELS
    • ESO EAST (Enhancing and Accelerating Stroke Treatment)
    • RES-Q — Registry of Stroke Care Quality
    • EU Research Partnerships
    • QASC
    • Stroke Action Plan for Europe (SAP-E)
    • Stroke Unit and Stroke Centre Certification
    • WISE
  • Resources
    • eSTEP
    • Emerging Leader Programme
    • European Master Programme in Stroke Medicine
    • Department to Department Visit Programme
    • ESO Trials Alliance
    • European Telestroke Networks
    • COVID-19 Resources
    • Task Force 4 Ukraine
  • News and Media
    • European Stroke Journal (ESJ)
    • Blog
    • Podcast
    • Paper of the Month
    • Press
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Non-HDL-cholesterol in the young -is it worth worrying?

27/02/2020/in ESO, Stroke Research /by Lara Le Noan

By Antje Schmidt-Pogoda, Fachärztin für Neurologie, Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster

Only recently, the treat stroke to target trial has demonstrated the benefit of aggressive LDL-cholesterol lowering for secondary stroke prevention.1 Depending on the overall cardiovascular risk and LDL-cholesterol levels, Current European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines also recommend LDL-cholesterol lowering for primary prevention of cardiovascular disease.

However, in young and otherwise healthy people, cholesterol levels are rarely determined. If increased, would this be worth worrying anyway?

A recent risk-evaluation and risk-modelling study from the Multinational Cardiovascular Risk Consortium sheds light on this important issue: Worrying about cholesterol is in fact worth it – even at young age.2 The study included data from almost 400 000 individuals with a maximum follow-up of 43.6 years (median 13.5). The mean age of participants was 51 years with one third at age<45 years. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of a coronary heart disease event or ischemic stroke. The study results show progressively higher 30-year cardiovascular disease event rates for increasing non-HDL-cholesterol categories (from 7·7% for non-HDL-cholesterol <2·6 mmol/L to 33·7% for ≥5·7 mmol/L in women and from 12·8% to 43·6% in men; p<0·0001). In women, a non-HDL value of 2.6 to 3.7 mmol/l was associated with a 10% increase in long-term risk of cardiovascular disease. The hazard ratio was significant with a 95% confidence interval of 1.0 to 1.3. A non-HDL value of over 5.7 mmol/l increased the long-term risk by 90% (hazard ratio 1.9; 1.6 to 2.2) and was most marked at age<45 years (hazard ratio 4.3; 3.0-6.1). The risk was similar for men: the hazard ratios were 1.1 (1.0 to 1.3) for non-HDL cholesterol from 2.6 to 3.7 mmol/l and 2.3 (2.0 to 2.5) for a non-HDL value of over 5.7 mmol/l. Again most prominent at age<45 years (4.6, 3.3-6.5)! These long-term calculations show that younger people are at risk even with slightly elevated cholesterol levels. The authors attribute this to an accumulating effect. Altogether, these findings pronounce that elevated non-HDL-cholesterol levels should be taken seriously in the young.

  1. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, et al. A comparison of two ldl cholesterol targets after ischemic stroke. N Engl J Med. 2019
  1. Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019

Recent Posts

  • Functional outcomes and quality of life after endovascular thrombectomy in large and extensive infarcts (ASPECTS 0–5): a multicentre registry study 13/11/2026
  • D2D Report – Michael Yirgalem Teka 06/11/2026
  • Train the Trainer workshop: learning to build our own stroke simulations 30/10/2026
  • Highlights from the 10th World Intracranial Hemorrhage Conference 23/10/2026
  • Beyond angiography: flat-panel imaging after thrombectomy 16/10/2026
  • D2D Report – Dimitar Mitsev 09/10/2026
  • The Expanding Role of Endovascular Therapy in Cerebral Venous Sinus Thrombosis 02/10/2026
  • ESJ Featured Article of the Month – September 2026: Anaesthesia during medium and distal vessel thrombectomy: a signal, not yet a strategy 25/09/2026
  • ESO TF4UKR D2D Report – Alina Trubetska 18/09/2026
  • Post-Stroke Complications 11/09/2026

Tags

2021 acute ischemic stroke brain cardiology career clinical D2D department to department visit emergency medicine ESJ ESO ESO-EAST ESOC ESOC 2018 ESOC 2019 ESOC 2022 ESOC 2023 ESOC 2024 ESOC 2025 ESOWSO2020 Europe European Stroke Journal FESO guidelines hospital interview ischaemic stroke ischemic stroke networking Neurology newsletter research SAFE stroke stroke care Stroke Center stroke in the young stroke research stroke treatment stroke trials TF4UKR TIA trials virtual YSPR

Archive

Categories

  • ESO
  • ESOC
  • IRT Post
  • Stroke Research

European Stroke Organisation
Reinacherstrasse 131
4053 Basel / Switzerland
E: esoinfo@eso-stroke.org

  • Home
  • ESO Conference
  • Blog
  • My ESO
  • Membership
  • Subscribe to our Newsletter
© ESO-STROKE 2024 — the Voice of Stroke in Europe
  • Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to Bluesky Link to BlueskyLink to Bluesky
  • Link to Instagram
  • Imprint
  • Privacy Statement
  • Disclaimer
  • Contact
Scroll to top Scroll to top Scroll to top